Overview
French animal health firm's FY 2025 sales slightly missed analysts' expectations
Essential Products sales grew 4.1% at constant exchange rates, driven by Q4 performance
Company faced historically high negative currency impacts, affecting overall sales
Outlook
Company expects to maintain solid profitability due to improved product mix
Result Drivers
ESSENTIAL PRODUCTS GROWTH - Essential Products sales increased by 4.1% at constant exchange rates, driven by strong Q4 performance
CURRENCY IMPACT - Negative currency impacts of €14.8 million affected sales outside Europe
PRODUCT RANGE SIMPLIFICATION - Simplification of Complementary product ranges led to a sales impact of -€9.7 million
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Slight Miss*
EUR 525.7 mln
EUR 528.05 mln (4 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Vetoquinol SA is €88.00, about 3.3% above its January 28 closing price of €85.20
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nBw8gc4tJa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
